Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Fixed-dose combo of sofosbuvir and velpatasvir is approved to treat genotypes 1-6 and be the first ribavirin-free regimen for genotypes 2 and 3 of the virus.